New York State Common Retirement Fund Sells 1,600 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

New York State Common Retirement Fund trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 4.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,215 shares of the biotechnology company's stock after selling 1,600 shares during the quarter. New York State Common Retirement Fund owned 0.07% of United Therapeutics worth $10,239,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Parallel Advisors LLC grew its holdings in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Signaturefd LLC boosted its stake in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares in the last quarter. Anchor Investment Management LLC boosted its stake in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after buying an additional 30 shares in the last quarter. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 6.2% in the fourth quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after buying an additional 48 shares in the last quarter. Finally, Dunhill Financial LLC boosted its stake in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

UTHR has been the topic of several research analyst reports. Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley reduced their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Finally, UBS Group dropped their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Stock Performance

Shares of UTHR traded down $5.32 during mid-day trading on Friday, reaching $292.01. 322,671 shares of the company were exchanged, compared to its average volume of 442,719. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a market capitalization of $13.17 billion, a PE ratio of 11.65, a PEG ratio of 6.31 and a beta of 0.53. The business has a 50 day simple moving average of $300.42 and a two-hundred day simple moving average of $318.13.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same quarter last year, the firm posted $6.17 earnings per share. The firm's revenue was up 17.2% on a year-over-year basis. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $300.31, for a total value of $3,303,410.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,045,702.11. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director directly owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,681 shares of company stock valued at $22,140,089 over the last ninety days. Insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.